Cancer Chemopreventive Properties of Cyanidin-3-Glucoside Revealed

Recent research from the University of Leicester, United Kingdom, has unveiled the cancer chemopreventive properties of cyanidin-3-glucoside (C3G), an anthocyanin component found in fruits and berries. The study, led by T.H. Marczylo, found that C3G possesses significant pharmacological activity in mouse models of carcinogenesis, with the potential to target various tissues, including the gastrointestinal mucosa, prostate, and kidneys.

Key Takeaways:

• C3G, an anthocyanin component of fruits and berries, exhibits cancer chemopreventive properties in mouse models of carcinogenesis.
• The pharmacokinetics and metabolism of C3G in mice have been studied, revealing peak concentrations of anthocyanins within 30 minutes after oral administration.
• After oral administration, C3G levels were highest in the urine and gastrointestinal mucosa, while after intravenous (iv) dosing, the majority of anthocyanins was C3G metabolites.
• The half-lives of C3G in different biofluids and tissues ranged from 0.7 to 1.8 h and 0.3 to 0.7 h after oral and iv administration, respectively.
• Systemic bioavailabilities for parent C3G and total anthocyanins were 1.7 and 3.3%, respectively.
• The major metabolites of C3G were products of methylation and glucuronidation, while cyanidin was a minor metabolite in the gut.
• The study's findings suggest that C3G and its metabolites may be effective in targeting cancer chemopreventive intervention in the gastrointestinal mucosa, prostate, and kidneys.
• The study's conclusion highlights the potential pharmacological activity of athocyanins, achieved in the gastrointestinal mucosa, prostate, and kidneys, which is of an order of magnitude consistent with pharmacological activity.
• The study provides insights into the pharmacokinetics and metabolism of C3G, which may lead to the development of novel cancer chemopreventive agents.

Statistics:

• Peak concentrations of anthocyanins occurred within 30 minutes after oral administration.
• Levels of C3G and its anthocyanin metabolites were highest in the urine (5.3 ± 0.2 %) and gastrointestinal mucosa (3.6 ± 0.2%).
• Systemic bioavailabilities for parent C3G and total anthocyanins were 1.7 and 3.3%, respectively.
• Half-lives of C3G in different biofluids and tissues ranged from 0.7 to 1.8 h and 0.3 to 0.7 h after oral and iv administration, respectively.

Sources:

• Marczylo, T. H., et al. "Pharmacokinetics and metabolism of the putative cancer chemopreventive agent cyanidin-3-glucoside in mice." Cancer Chemotherapy and Pharmacology 64.6 (2009): 1261-1268.
• University of Leicester, Cancer Biomarkers & Prevention Group, Dept. of Cancer Studies & Molecular Medical, RKCSB, LRI, Leicester LE2 7LX, Leics, UK.
• Springer, 233 Spring St., New York, NY 10013, USA.
• Cancer Weekly, via NewsRx.com.